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Summary
Objective: Limited data are available regarding the evolution over time of the
rate of sudden unexpected death in epilepsy patients (SUDEP) in drug-resistant
epilepsy. The objective is to analyze a database of 40 443 patients with epilepsy
implanted with vagus nerve stimulation (VNS) therapy in the United States (from
1988 to 2012) and assess whether SUDEP rates decrease during the postimplanta-
tion follow-up period.
Methods: Patient vital status was ascertained using the Centers for Disease Con-
trol and Prevention’s National Death Index (NDI). An expert panel adjudicated
classification of cause of deaths as SUDEP based on NDI data and available nar-
rative descriptions of deaths. We tested the hypothesis that SUDEP rates decrease
with time using the Mann-Kendall nonparametric trend test and by comparing
SUDEP rates of the first 2 years of follow-up (years 1-2) to longer follow-up
(years 3-10).
Results: Our cohort included 277 661 person-years of follow-up and
3689 deaths, including 632 SUDEP. Primary analysis demonstrated a significant
decrease in age-adjusted SUDEP rate during follow-up (S = 27 P = .008), with
rates of 2.47/1000 for years 1-2 and 1.68/1000 for years 3-10 (rate ratio 0.68;
95% confidence interval [CI] 0.53-0.87; P = .002). Sensitivity analyses confirm
these findings.
Significance: Our data suggest that SUDEP risk significantly decreases during
long-term follow-up of patients with refractory epilepsy receiving VNS Therapy.
This finding might reflect several factors, including the natural long-term dynamic
of SUDEP rate, attrition, and the impact of VNS Therapy. The role of each of
these factors cannot be confirmed due to the limitations of the study.
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1 | INTRODUCTION
Sudden unexpected death in epilepsy (SUDEP) is the
second leading neurological cause of years of potential
life lost in the United States.1 Recent practice guidelines
of the American Academy of Neurology indicate that
the risk of SUDEP is 1.2/1000 patient-years (95% confi-
dence interval [CI] 0.64-2.32) in adults with epilepsy,
and 0.22/1000 patient-years in children.2 Comparable
figures were recently reported in a Swedish population-
based study with a SUDEP rate of 1.2/1000 patient-
years (95% CI 0.93-1.52).3 This risk increases up to
5.9/1000 patient-years in patients with chronic refractory
epilepsy.4 However, the majority of epidemiological
studies have been cross-sectional, thereby lacking infor-
mation on the evolution of SUDEP rate over time. A
long-term, prospective, follow-up study of an unselected
cohort of Finnish patients with childhood-onset epilepsy,
showed a cumulative SUDEP incidence rate of 22%
(95% CI, 14%-30%) over a 40-year follow-up period
among patients who were not in 5-year terminal remis-
sion.5 However, the sample size was too limited to reli-
ably estimate changes in SUDEP rates over time.
Exploring SUDEP incidence in large datasets of patients
with refractory epilepsy and long-term follow-up might
thus provide important information on the evolution of
SUDEP incidence over time, as well as on potential pre-
ventive intervention.6
VNS Therapy (Cyberonics, Inc./LivaNova, Houston,
TX, USA) implants are recorded by the manufacturer in its
Device Tracking Database when information is provided
by the implanting facilities. Using data through 31 Decem-
ber 2012, information was available on a large dataset of
40 443 patients in the United States with 277 661 person-
years (PY) of follow-up. Here we report the results from
our analysis of this database to understand the evolution of
SUDEP risk over time.
2 | METHODS
The study protocol (see Data S1) and data collection
methods were developed by the study coauthors in
accordance with the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) state-
ment.7 Although the protocol was designed to assess all-
cause mortality rates and several specific causes of death,
the current study focuses only on SUDEP-related analy-
ses. Institutional Review Board approval was received
prior to receiving vital status from the Centers for Dis-
ease Control and Prevention’s National Death Index
(NDI).
2.1 | Study population
The VNS Therapy Device Tracking Database is maintained
by the manufacturer and includes information on patients
who are implanted with the VNS Therapy device. The
population included in this analysis were implanted for
epilepsy between 16 November 1988 and 31 Decem-
ber 2012.8 The database includes the patient name, date of
birth, US Social Security Number, indication treated, and
the dates of implantation surgery, explantation surgery, and
death (if applicable).
Patients were included in the study analysis if they met
the following criteria: (1) implanted with VNS Therapy by
December 31, 2012 (ie, the study end date) based on a
diagnosis of epilepsy, (2) were a US citizen or resided in
the United States at the time of implant, (3) had a US
Social Security Number, and (4) had a known date of
birth.
2.2 | Ascertainment of deaths and SUDEP
The study was based on data collected by the National
Center for Health Statistics with the causes of death in the
United States classified in accordance with the International
Classification of Diseases (ICD) Ninth Revision (ICD-9;
for data prior to 1999) and Tenth Revision (ICD-10; for
data starting from 1999). Using the available unique patient
identification information from the VNS Device Tracking
Database, data on all study patients were submitted to the
NDI9 for ascertainment of vital status and cause of death.
The latter included an underlying cause of death (UCD)
Key Points
• A total of 40 443 patients with VNS Therapy
were followed up to 10 years postimplantation,
accumulating 277 661 person-years of follow-up
• There were 3689 deaths, including 632 SUDEP,
with 84% classified as possible and 16% as prob-
able or definite
• Age-adjusted SUDEP rates decreased signifi-
cantly over time (by over 30%) from years 1 to 2
(2.47/1000 person-years) to years 3 to 10 (1.68/
1000 person-years)
• Several mechanisms could account for these find-
ings including attrition and natural evolution,
aging, changes in medications or medical prac-
tice over time, or VNS Therapy; the respective
impacts cannot be disentangled due to study lim-
itations
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and up to 20 contributory causes of death (CCDs). Other
information available in all deceased patients were gender,
age at VNS implant (corresponding to the time of onset of
follow-up within the study), and age at death.
When a death was reported to Cyberonics by the
patient’s family or physician, the company collected infor-
mation regarding the details surrounding the death and
autopsy findings, when available, as part of their US Food
and Drug Administration (FDA)–mandated complaint-
handling process. Such information was transcribed into
narratives by Cyberonics at the time of each report and
reviewed by an expert panel as part of this study.
It is important to note that no further clinical informa-
tion was available in this study, such as age at epilepsy
onset, epilepsy duration, and seizure frequency and its evo-
lution under VNS therapy.
SUDEP was defined according to criteria published by
Annegers (1997),10 that is, the victim had epilepsy, defined
as recurrent unprovoked seizures; the victim died unexpect-
edly while in a reasonable state of health, the death
occurred “suddenly” (in minutes), when known; the death
occurred during normal activities (eg, in or around bed, at
home, at work) and benign circumstances; and an obvious
medical cause of death was not found. SUDEP was consid-
ered definite when all criteria were met, and postmortem
data were available, probable when all criteria were met
without postmortem data, and possible when SUDEP could
not be ruled out but there was insufficient evidence regard-
ing the circumstances of the death and no postmortem
report was available. Unlikely/Not SUDEP was considered
when the cause of death was clearly established, or the cir-
cumstances make SUDEP highly improbable.
SUDEP cannot be directly extracted from NDI data,
since there is no corresponding ICD code in the ICD-9/
ICD-10 classification. Thus adjudication of SUDEP
required a specific procedure that was developed by the
SUDEP expert panel of the study and included all available
data, in particular, age at death, UCD and CCD recorded in
the NDI, and death narratives as collected by Cyberonics
in a subset of patients. This procedure included the follow-
ing 3 steps.
The first step consisted of the development and process-
ing of an algorithm that identifies combinations of UCD
and CCD likely compatible with the diagnosis of SUDEP.
The expert panel (DF, DH, ES, MS, OD, and PR) in
charge of developing this algorithm was exposed to the list
of UCD recorded in the database, from which it selected
41 UCD pooled into 3 groups (see Table 1 for details)
reflecting the main situations encountered in NDI transcrip-
tion of SUDEP: (1) group 1, epilepsy or seizure is consid-
ered as the UCD. In this group, an exclusion criterion was
the presence of status epilepticus among CCD; (2) group 2,
UCD is quoted as “other ill-defined and unspecified causes
of mortality” or as an acute cardiac or respiratory disorder
such as “cardiac arrest, unspecified,” “anoxic brain damage,
not elsewhere classified,” or “unspecified threat to breath-
ing.” In this group, an exclusion criterion was the presence
of another well-defined life-threatening cardiorespiratory
disorder such as ischemic heart disease or asthma; (3)
group 3: UCD is a congenital brain disorder, primarily
cerebral palsy and mental retardation, although such condi-
tions are usually not directly responsible for death. In this
group, an additional inclusion criterion was that epilepsy or
seizure should be listed among CCDs. This algorithm was
run automatically among all deceased patients to select the
per-protocol population used for the next steps of SUDEP
adjudication.
The second step consisted of exploring the subset of
patients with a death narrative and evaluating the corre-
spondence between these narratives and combinations of
UCD and CCD, to increase the accuracy of SUDEP adjudi-
cation based on UCD/CCD alone in patients without death
narrative.
The third step was the adjudication of all cases selected
through step 1, based on all available information and
knowledge gained from step 2. A panel of 2 neurologists
(DF and PR) independently performed this task, blinded to
the duration of follow-up in the study. In all cases where
the first 2 neurologists did not agree exactly on the SUDEP
classification level, a third neurologist (ES) performed a
final independent adjudication. Finally, the 3 investigators
discussed during teleconferences all cases where they
initially disagreed in order to better understand reasons
for disagreement and see whether they could reach a
consensus.
2.3 | Sensitivity analyses
Because of the level of uncertainty of SUDEP ascertain-
ment in patients without a death narrative, an alternative
adjudication “by extrapolation” was used, whereby the rate
of adjudicated SUDEP of cases with a narrative within
each year of follow-up was prescribed to the cases without
a narrative in the same year of follow-up. Furthermore, all
analyses were repeated for the subset of patients who were
10 to 54 years old with the view to exclude younger
patients whose risk of SUDEP is very low, and older
patients who often have coexisting, competing medical
causes of death. The same analyses were also performed
on the subset of definite and probable SUDEP.
2.4 | Statistical analysis
Patient exposure was calculated from date of implantation
until death, device explantation, known date at which the
device was disabled, or the last follow-up date of 31
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December 2012. Both crude and directly standardized (ie,
age-adjusted) SUDEP rates were reported per 1000 PY of
follow-up along with 95% CI. The directly standardized
rates used the U.S. Standard Population for 200011 and age
ranges of 0-4, 5-9, 10-14, 15-19, 20-24, 25-34, 35-44, 45-
54, 55-64, 65-74, and 75+ years to match the census data.
For each patient, we calculated the number of years of fol-
low-up that were spent in each age group. Deaths were
TABLE 1 Underlying cause of death in the per-protocol population (N = 953 patients)
Underlying cause of death (UCD) as recorded in the national death index (NDI) N %
Epilepsy and seizure 578 60.7
Epilepsy, unspecified [G40.9, 345.9] 266 27.9
Other and unspecified convulsions [R56.8] 242 25.4
Grand mal seizures, unspecified (with or without petit mal) [G40.6] 28 2.9
Generalized idiopathic epilepsy and epileptic syndromes [G40.3] 19 2.0
Other generalized epilepsy and epileptic syndromes [G40.4] 16 1.7
Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes [G40.1; G40.2] 5 0.5
Other epilepsy [G40.8] 2 0.2
Ill-defined and cardiorespiratory 61 6.4
Other ill-defined and unspecified causes of mortality [R99] 49 5.1
Anoxic brain damage, not elsewhere classified [G93.1] 46 4.8
Cardiac arrest, unspecified [I46.9] 25 2.6
Cardiac arrhythmia, unspecified [I49.9] 22 2.3
Unspecified threat to breathing [W84] 11 1.2
Sudden cardiac death, so described [I46.1] 7 0.7
Sleep apnea [G47.3] 4 0.4
Accidental suffocation and strangulation in bed [W75] 3 0.3
Other specified threats to breathing [W83] 3 0.3
Asphyxia [R09.0, 799.0] 2 0.2
Respiratory arrest [R09.2] 2 0.2
Ventricular fibrillation and flutter [I49.0] 2 0.2
Ventricular tachycardia [I47.2] 2 0.2
Cardiac arrest [427.5] 1 0.1
Cardiac dysrhythmias, unspecified [427.9] 1 0.1
Preexcitation syndrome [I45.6] 1 0.1
Instantaneous death [R96.0] 1 0.1
Cerebral palsy/mental retardation 193 20.3
Infantile cerebral palsy, unspecified [G80.9, 343.9] 121 12.7
Unspecified mental retardation [F79] 34 3.6
Severe mental retardation [F72] 9 0.9
Childhood autism [F84.0] 6 0.6
Other infantile cerebral palsy [G80.8] 4 0.4
Profound mental retardation [F73] 4 0.4
Rett’s syndrome [F84.2] 4 0.4
Disorder of brain, unspecified [G93.9] 3 0.3
Spastic cerebral palsy [G80.0] 2 0.2
Mild mental retardation [F70] 2 0.2
Unspecified disorder of psychological development [F89] 2 0.2
Infantile hemiplegia [G80.2] 1 0.1
Other specified disorders of brain [G93.8] 1 0.1
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assigned to the patient’s age group at the time of death. All
analyses were performed after pooling definite, probable,
and possible SUDEP, except sensitivity analyses focusing
on definite and probable SUDEP only.
The hypothesis that SUDEP rates decrease with time on
VNS Therapy was first assessed by testing for a decreasing
SUDEP hazard rate over follow-up time12 and applying the
Mann-Kendall nonparametric trend test to the SUDEP rates
by year of follow-up.13 In addition, the 95% CI was calcu-
lated for the rate ratio of the last 8 years postimplantation
divided by the first 2 years postimplantation with the view
to compare our findings to those of the 2 previous reports
of SUDEP in patients undergoing VNS that used that
methodology.
The Barlow-Campo test was performed by counting the
number of times the total time on test (TTT) plot crosses a
45-degree line; a small number of crossings indicates that
the hazard rate is nonconstant and is either decreasing (the
TTT plot lies below the 45-degree line) or increasing (the
TTT plot lies above the 45-degree line).11
We performed additional analyses to test the potential
impact of changes in calendar year and aging on our find-
ings. First, we calculated and compared the average date
during follow-up for patients at years 1 and 2, vs years 3
to 10 post-VNS implant. Secondly, the age-adjusted
SUDEP rates during the first full year of VNS Therapy
were tested for a decreasing hazard rate over calendar
years to detect changes in SUDEP rate over time indepen-
dent of the duration of VNS Therapy. Finally, we calcu-
lated the theoretical number of cases of SUDEP that
should have occurred in our cohort during years 3 to 10
of follow-up, provided that the risk of SUDEP would
remain the same in each age group as that observed during
years 1 and 2. The duly observed number of deaths was
divided by the expected number of deaths to calculate a
standardized mortality ratio (SMR) per the indirect stan-
dardization method, with 95% CI calculated using the Byar
approximation.14
Statistical analyses were performed using JMP Ver-
sion 9, Minitab 17, and SAS Version 9.3 (SAS Institute
Inc., Cary, NC, USA).
3 | RESULTS
3.1 | Study participants
According to implant registrations, 57 551 patients were
implanted with VNS Therapy systems in the United States
between 16 November 1988 and 31 December 2012. Of
these patients, 40 443 (70%) met the inclusion criteria for
this analysis. The average age at implantation was
30.8 years (range, 0-89) with 15% of the patients under
12 years of age. Fifty percent of the patients were male.
There were 277 661 PY of follow-up with a median dura-
tion of follow-up of 7.6 years. Of the 40 443 patients,
12 037 (30%) had completed at least a 10-year follow-up
period, 21 853 (54%) were implanted after 2002 and were
alive and receiving VNS Therapy as of the analysis cutoff
date, 2864 (7%) had their device explanted or known to be
turned off prior to the cutoff date, and 3689 (9%) died
within the study analysis period. The all-cause mortality
rate was 13.3 per 1000 PY of follow-up (95% CI, 12.9-
13.7), translating into an age- and gender-adjusted SMR of
4.58 (95% CI, 4.43-4.73).
3.2 | SUDEP adjudication
Step 1: of the 3689 deaths, 953 (25.8%) were associated
with UCD and CCD considered compatible with SUDEP
and selected by our algorithm, including 578 (61%, 95% CI
[57%-64%]) in group 1 (epilepsy/seizure), 181 (19%, 95%
CI [16%-22%]) in group 2 (ill-defined and cardiorespiratory
UCD), and 194 (20%, 95% CI [18%-23%] in group 3 (con-
genital brain disorders) (see Table 1).
Step 2: A death narrative was available in 408 of these
953 patients (43%), including 263 in group 1 (65%, 95%
CI [60%-69%]), 74 in group 2 (18%, 95% CI [14%-22%]),
and 71 in group 3 (17%, 95% CI [14%-21%]). Among
these 408 patients with a death narrative, one or several
potentially life-threatening CCDs that would exclude
SUDEP were recorded in 56 patients (14%). The most fre-
quent CCD, accounting for 36 of these 56 cases (64%),
were related to aspiration and/or pulmonary infection with
the following axis codes: “pneumonitis due to food and
vomit,” “foreign body in respiratory tract” usually associ-
ated with “inhalation and ingestion of other objects causing
obstruction of respiratory tract,” and “pneumonia.” These
were primarily encountered in patients from group 3 with
cerebral palsy and severe mental retardation (22 of 36 such
CCD). The second most frequent CCD was drowning
encountered in 8 patients (14%), primarily in bathtub. The
remaining CCD each occurred only once in 11 patients,
and included various axis codes such as “Acute renal fail-
ure,” “Hyperkalemia,” “Asthma, unspecified,” “Cachexia,”
“Chronic renal failure,” “Edema of larynx,” “Hemorrhage,
not elsewhere classified,” “Pneumothorax,” “Pulmonary
edema,” “Status epilepticus,” “Fracture of neck,” and
“Acute myocardial infarction.” The death narratives of
these 56 patients confirmed the relevance of the above
CCDs in most instances, with only 3 cases (5%; 95% CI
[0%-12%]) where the CCD was disproved by the detailed
description of the circumstances of death available for all 3
patients and autopsy findings in 1 patient, leading to adju-
dication of SUDEP in all cases (one definite, one probable,
one possible). In the 352 patients with a death narrative
and no CCDs that would exclude SUDEP, the proportion
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of cases where the narrative permitted the adjudication
SUDEP dramatically varies between groups, with 87%
(95% CI [82%-91%]) in group 1, 81% (95% CI [71%-91%])
in group 2, but only 49% in group 3 (95% CI [34%-64%]).
In the latter group, many patients with cerebral palsy and
severe mental retardation would be described as dying in-
hospital or in a specialized institution following aspiration
and/or end-stage respiratory infection, even though these
conditions were not listed among CCDs.
Overall step 2 suggested that the following statements
could be used to help adjudicate cases without death narra-
tive, based on UCD and CCD alone: (1) the presence of
CCDs representing potentially life-threatening conditions
that would exclude SUDEP permits the adjudication of such
cases as Not SUDEP with a level of confidence of 95%; (2)
patients whose UCD falls into groups 1 and 2 categories (epi-
lepsy, seizure, cardiac arrest or dysrhythmia, threat to breath-
ing, ill-defined cause of death) with no CCDs excluding
SUDEP, are very likely to have SUDEP (above 80%); (3)
patients whose UCD corresponds to nondirectly lethal con-
genital brain disorders, such as cerebral palsy and mental
retardation, and in whom no CCDs exclude SUDEP, have
<50% of chances to have had SUDEP.
Step 3: Among the 953 potential SUDEP selected at step
1, the 2 reviewers disagreed on adjudicating death as SUDEP
or not SUDEP in 79 cases (8.3%) for a Cohen’s kappa value
of 0.81 (95% CI, 0.76-0.85). They also disagreed in another
94 cases (9.7%) on the classification level of SUDEP. Fol-
lowing the evaluation of these 173 discordant cases by the
third reviewer, adjudication per-protocol resulted in 632
SUDEP (66.3%) classified as definite (n = 38; 4%), probable
(n = 63; 7%), and possible (n = 531; 56%) (Table S1), with
an overall crude SUDEP rate of 2.28/1000 PY of follow-up
(95% CI, 2.10-2.46). Following discussions of all cases with
disagreements between the 3 adjudicators, most disagree-
ments appeared to result from failures to identify important
information in the death narrative or among CCDs. The 3
experts eventually reached a consensus conclusion in all
cases, resulting in a total of 638 SUDEP (66.9%), almost
identical to that of the per-protocol adjudication.
Adjudication by extrapolation used for sensitivity analy-
sis resulted in a total of 667 SUDEP (70.0%) and 286 not
SUDEP (30.0%).
3.3 | SUDEP rates during follow-up period
The annual age-adjusted SUDEP rates in our per-protocol
population significantly decreased with the duration of fol-
low-up (nonparametric Mann-Kendall trend test, S = 27,
P = .008) (Table 2). Nonparametric tests based on survival
analysis confirmed that the hazard rate of SUDEP includ-
ing all patient ages decreases with duration of follow-up
(Barlow-Campo Ln = 1, P = .001). This was graphically
observed from year 1 (2.73/1000 PY) to year 9 (1.23/1000
PY), with a rebound at year 10 (2.09/1000 PY) (Figure 1).
Comparable findings were observed for crude SUDEP rates
(S = 27, P = .008) and sensitivity analyses restricted to
the 10-54 age range, except for the lack of rebound at
10 years in the latter age range (S = 35, P < .001)
(Table 2 and Figure 2). Accordingly, the crude and age-
adjusted SUDEP rates during years 3 to 10 of follow-up
(2.10/1000 PY, 1.68/1000 PY) were significantly lower
than those observed during the first 2 years of follow-up
(2.74/1000 PY; 2.47/1000 PY), with rate ratios of 0.77
(95% CI, 0.65-0.91, P = .002) and 0.68 (95% CI, 0.53-
0.87, P = .002), respectively (Table 2).
Adjudication by extrapolation provided comparable
results with significant outcomes for all 4 rate ratios and 3
of the 4 Mann-Kendall trend tests with the exception of a
nonsignificant decreasing trend for one age-adjusted analy-
sis (S = 17, P = .078) (Table 2 and Figures S1 and S2).
Similarly, when only considering definite and probable
SUDEP, both crude and age-adjusted Mann-Kendall trend
tests, and the rate ratio comparing years 3 to 10 to the first
2 years of follow-up, showed a highly significant decreased
SUDEP rate over time (see Table 2).
SUDEP rates during the first year of VNS Therapy as a
function of calendar year did not decrease significantly
between 1999 and 2012 (S = 25, P = .096) (Figure 3).
Furthermore, because new patients entered the cohort dur-
ing the entire study period, the average date of follow-up
for patients at years 1 and 2 post-VNS implantation
(December 2004) was only 3 years earlier than for patients
at years 3 to 10 post-VNS implantation (December 2007).
We calculated that 566 SUDEP cases should have been
observed during years 3 to 10 of follow-up if the risk of
SUDEP per age group would remain the same as that
observed during the first 2 years of follow-up. This trans-
lated into an SMR of 0.75 (95% CI, 0.68-0.82) in compar-
ison with the 423 SUDEP duly observed during years 3 to
10 of follow-up (Table 3).
To better understand the pace of reduction in SUDEP
rate over time, we investigated the crude and age-adjusted
SUDEP rates by trimester during the first 2 years post-
VNS implantation. As illustrated in Figure S3, these rates
appear to remain relatively stable during this period.
4 | DISCUSSION
The primary finding from this large longitudinal long-term
cohort study is the observation that SUDEP rates decrease
over time in patients with drug-resistant epilepsy being
treated with adjunctive VNS Therapy. The decrease in
SUDEP rate appears to be sustained until the ninth year of
follow-up postimplantation, translating into an overall 25%
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reduction in the number of SUDEP events expected to
occur in this cohort under the hypothesis of stable age-
adjusted SUDEP rate during follow-up. The information
that individual risk of SUDEP might decrease over time in
patients with refractory epilepsy has not been previously
reported in the literature and would be of value for patients
at risk of SUDEP.
The paucity of individual data available in our cohort is
responsible for several limitations. Thus one major short-
coming of this study is that only 16% of SUDEP could be
ascertained as definite or probable. In most other cases
adjudicated as possible SUDEP, description of the circum-
stances of death was not sufficiently detailed to support a
more robust diagnosis, although death certificate or narra-
tive did not suggest any other clear-cut cause of death.
Although based on weaker evidence, adjudication of possi-
ble SUDEP was consolidated by the independent assess-
ment of 3 experts who, when invited to discuss disagreed
cases, reached a consensus in all cases. Most important to
note is that, our goal was not to provide precise epidemio-
logical figures of SUDEP, but to select deaths likely to be
due to SUDEP and of sufficient number to test the impact
of duration of follow-up on such deaths. From a patient
perspective, this latter finding might be more relevant than
observations based on restricted cases of probable and defi-
nite SUDEP assessed in much smaller populations.
FIGURE 1 SUDEP rate during VNS
postimplantation follow-up adjudicated
according to protocol (N = 632 SUDEP).
The crude (red line) and age-adjusted (blue
line) SUDEP rates per 1000 person-years of
follow-up are shown for years 1 to 10 post-
VNS implantation. The Mann-Kendall trend
tests showed a significant reduction of
crude and age-adjusted SUDEP rate with
duration of follow-up (S = 27, P = .008
for both rates)
FIGURE 2 SUDEP rate during VNS
postimplantation follow-up adjudicated
according to protocol in patients aged 10 to
54 (N = 560 SUDEP). The crude (red line)
and age-adjusted (blue line) SUDEP rates
per 1000 person-years of follow-up are
shown for years 1 to 10 post-VNS
implantation. The Mann-Kendall trend tests
showed a significant reduction of crude and
age-adjusted SUDEP rate with duration of
follow-up (S = 37, P < .001 for crude
rate and S = 35, P < .001 for age-
adjusted rate)
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Another limitation of our findings is the interpretation of
the decreased rate of SUDEP over time. In particular, the
direct role of VNS Therapy cannot be assessed due to the
lack of preimplantation baseline, lack of a control group, and
lack of information on individual responses to VNS Therapy.
In fact, it could be that the risk of SUDEP during first
2 years of VNS treatment differs, in one direction or the
other, from the preimplantation baseline. One might also
challenge whether the level of antiepileptic efficacy demon-
strated in pivotal randomized trials of VNS15,16 could explain
the reduction in SUDEP rate observed in our cohort. In fact,
a meta-analysis of randomized controlled trials (RCTs) of
add-on antiepileptic drugs (AEDs) in drug-resistant epilepsy,
with an effect size on seizure frequency comparable to that
of VNS, showed that the risk of SUDEP was decreased by 7-
fold in patients receiving an add-on AED as compared to
those allocated to placebo.17
Several other mechanisms could account for our findings
including attrition and natural evolution, aging, or changes in
medications or medical practice over time. Indeed, one might
hypothesize that patients at highest risk of SUDEP might
preferentially die during the first 2 years following VNS
FIGURE 3 SUDEP rate adjudicated
according to protocol during the first year
post-VNS implantation. The age-adjusted
SUDEP rates per 1000 person-years of
follow-up are shown for calendar years
1999 to 2012
TABLE 3 Impact of aging on SUDEP rate and number
Age group
Theoretical number of SUDEP in years 3-
10 extrapolated from observations in years
1-2
Number and rate of SUDEP truly observed
in years 3-10
SUDEP rate
per age group
in years 1-2
Number of
SUDEP
expected in
years 3-10
Number of
SUDEP
observed in
years 3-10
SUDEP rate per
age group in
years 3-10
0-4 0 0 0 0
5-9 1.80 12.5 3 0.43
10-14 2.10 32.6 12 0.77
15-19 1.67 30.8 38 2.06
20-24 3.50 68.9 42 2.14
25-34 3.51 134.1 84 2.20
35-44 3.54 147.1 118 2.84
45-54 2.75 100.4 78 2.14
55-64 1.91 35.2 46 2.50
65+ 0.72 4.1 2 0.35
Overall 2.81 565.7 423 2.10
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implantation. Cross-sectional epidemiological data rather
suggest that SUDEP rate increases with epilepsy duration
>15 years as compared to ≤15 years (odds ratio [95% CI]
1.95 [1.45-2.63]).18 However, we have no information
regarding the natural evolution of SUDEP rates for longer
epilepsy duration, and do not know the duration of epilepsy
in our cohort. The role of aging in driving our main finding
appears unlikely according to our age-adjusted analyses and
simulation of the effect of aging on the individual risk of
SUDEP during years 3-10 of VNS Therapy. The censored
group of 2864 patients who had their device explanted or
turned off prior to the cutoff date is also unlikely to influence
the SUDEP trends over time, as this group represented a
small and consistent 1% of patients each year post VNS
implantation. The possibility that new AEDs made available
during this study could have influenced our findings also
seems unlikely according to a difference of only 3 calendar
years between the average follow-up dates of years 1 and 2
and years 3 to 10 postimplantation and lack of a significant
reduction in SUDEP rate during the first year of post VNS
implantation over a 13-year period.
Our finding of a sustained reduction in SUDEP rate in
patients undergoing VNS Therapy is consistent with one of
the 2 small-scale studies previously published.19 A SUDEP
rate of 5.5/1000 PY of follow-up (95% CI, 2.8-9.8) was
observed during the first 2 years postimplantation, which
decreased to 1.7/1000 PY of follow-up (95% CI, 0.2-6.1)
thereafter. However, another single-center study with 10
SUDEP cases reported no difference between the first
2 years of VNS Therapy (3.4/1000 PY [95% CI, 0.7-10])
and the following years (3.3/1000 PY [95% CI, 1.3-6.8]).20
Our data fall into the confidence intervals reported in these
2 series (Figure S4). However, the value of such compar-
ison is hampered by the fact that our cohort includes a
majority of possible SUDEP, whereas the other studies
only considered definite and probable SUDEP. There might
be several mechanisms by which VNS could participate to
decrease SUDEP rate over time. Open-label series suggest
that VNS reduces the frequency of generalized tonic–clonic
seizure, the main SUDEP risk factor in focal and general-
ized epilepsies,21–24 and that the time-frame increase in sei-
zure reduction is consistent with that of SUDEP reduction
reported herein.25 VNS stimulation may also reduce the
duration and severity of the ictal and postictal phases,26
which could mitigate some of the mechanisms contributing
to seizure-induced SUDEP.
An intriguing, yet unexplained, finding is the apparent
rise in the risk of SUDEP at year 10 of follow-up. It
appeared to be primarily driven by the very rare cases of
SUDEP occurring in children younger than 10, and was
not observed in the population aged 10-54, suggesting the
possibility of a random fluctuation of SUDEP rate in very
young patients.
Overall, long-term follow-up of patients with drug-
resistant epilepsy undergoing VNS Therapy suggests that
the risk of SUDEP significantly decreases over time for
reasons that remain uncertain and deserve to be further
explored. However, according to the 25% reduction of
SUDEP rate observed in the study, a 3-year-long RCT
would need to enroll a minimum of 28 000 patients in
each arm of adjunctive VNS vs treatment-as-usual, which
is not feasible. Novel biomarkers highly predictive of
SUDEP will be needed to make prospective studies of
SUDEP prevention feasible in an enriched population.
Until then, only large retrospective cohorts, such as the
study presented here, can help us make progress in
SUDEP prevention, an issue that one should acknowledge
when weighing the limitations and value of currently
available data.
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